Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer.

Solinas C, Migliori E, De Silva P, Willard-Gallo K.

Cancers (Basel). 2019 Aug 20;11(8). pii: E1213. doi: 10.3390/cancers11081213. Review.

2.

Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.

Garaud S, Buisseret L, Solinas C, Gu-Trantien C, de Wind A, Van den Eynden G, Naveaux C, Lodewyckx JN, Boisson A, Duvillier H, Craciun L, Ameye L, Veys I, Paesmans M, Larsimont D, Piccart-Gebhart M, Willard-Gallo K.

JCI Insight. 2019 Aug 13;5. pii: 129641. doi: 10.1172/jci.insight.129641.

3.

Targeting PD-1 in cancer: Biological insights with a focus on breast cancer.

Solinas C, Aiello M, De Silva P, Gu-Trantien C, Migliori E, Willard-Gallo K.

Crit Rev Oncol Hematol. 2019 Oct;142:35-43. doi: 10.1016/j.critrevonc.2019.07.011. Epub 2019 Jul 21. Review.

PMID:
31357142
4.

Immune evasion before tumour invasion in early lung squamous carcinogenesis.

Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G, Buttard B, Rothe F, Willard-Gallo K, Haller A, Ninane V, Burny A, Sculier JP, Spira A, Galon J.

Nature. 2019 Jul;571(7766):570-575. doi: 10.1038/s41586-019-1330-0. Epub 2019 Jun 26.

PMID:
31243362
5.

The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History.

Mignon S, Willard-Gallo K, Van den Eynden G, Salgado R, Decoster L, Marien KM, Vansteenkiste JF, Teugels E, De Grève J.

Pathol Oncol Res. 2019 Jun 21. doi: 10.1007/s12253-019-00670-9. [Epub ahead of print]

PMID:
31228073
6.

Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features.

Porcu M, De Silva P, Solinas C, Battaglia A, Schena M, Scartozzi M, Bron D, Suri JS, Willard-Gallo K, Sangiolo D, Saba L.

Cancers (Basel). 2019 Mar 5;11(3). pii: E305. doi: 10.3390/cancers11030305. Review.

7.

BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.

Solinas C, Marcoux D, Garaud S, Vitória JR, Van den Eynden G, de Wind A, De Silva P, Boisson A, Craciun L, Larsimont D, Piccart-Gebhart M, Detours V, t'Kint de Roodenbeke D, Willard-Gallo K.

Cancer Lett. 2019 May 28;450:88-97. doi: 10.1016/j.canlet.2019.02.027. Epub 2019 Feb 22.

PMID:
30797818
8.

Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients.

Chi VLD, Garaud S, De Silva P, Thibaud V, Stamatopoulos B, Berehad M, Gu-Trantien C, Krayem M, Duvillier H, Lodewyckx JN, Willard-Gallo K, Sibille C, Bron D.

BMC Cancer. 2019 Jan 17;19(1):81. doi: 10.1186/s12885-019-5276-2.

9.

FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer.

De Silva P, Garaud S, Solinas C, de Wind A, Van den Eyden G, Jose V, Gu-Trantien C, Migliori E, Boisson A, Naveaux C, Duvillier H, Craciun L, Larsimont D, Piccart-Gebhart M, Willard-Gallo K.

EBioMedicine. 2019 Jan;39:226-238. doi: 10.1016/j.ebiom.2018.11.066. Epub 2018 Dec 20.

10.

Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer.

Garaud S, Zayakin P, Buisseret L, Rulle U, Silina K, de Wind A, Van den Eyden G, Larsimont D, Willard-Gallo K, Linē A.

Front Immunol. 2018 Nov 20;9:2660. doi: 10.3389/fimmu.2018.02660. eCollection 2018.

11.

Cancer immunotherapy-associated hypophysitis.

Solinas C, Porcu M, De Silva P, Musi M, Aspeslagh S, Scartozzi M, Willard-Gallo K, Mariotti S, Saba L.

Semin Oncol. 2018 Jun;45(3):181-186. doi: 10.1053/j.seminoncol.2018.09.002. Epub 2018 Oct 21. Review.

PMID:
30352754
12.

Quantifying Tertiary Lymphoid Structure-Associated Genes in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissues.

Gu-Trantien C, Garaud S, Migliori E, Solinas C, Lodewyckx JN, Willard-Gallo K.

Methods Mol Biol. 2018;1845:139-157. doi: 10.1007/978-1-4939-8709-2_9.

PMID:
30141012
13.

Immunity drives TET1 regulation in cancer through NF-κB.

Collignon E, Canale A, Al Wardi C, Bizet M, Calonne E, Dedeurwaerder S, Garaud S, Naveaux C, Barham W, Wilson A, Bouchat S, Hubert P, Van Lint C, Yull F, Sotiriou C, Willard-Gallo K, Noel A, Fuks F.

Sci Adv. 2018 Jun 20;4(6):eaap7309. doi: 10.1126/sciadv.aap7309. eCollection 2018 Jun.

14.

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.

Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C.

J Natl Cancer Inst. 2019 Jan 1;111(1):69-77. doi: 10.1093/jnci/djy076.

15.

Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?

Porcu M, Solinas C, Garofalo P, de Azambuja E, Scartozzi M, Willard-Gallo K, Preusser M, Saba L.

Crit Rev Oncol Hematol. 2018 Jun;126:135-144. doi: 10.1016/j.critrevonc.2018.03.026. Epub 2018 Apr 7. Review. No abstract available.

PMID:
29759556
16.

The impact of tumor cell metabolism on T cell-mediated immune responses and immuno-metabolic biomarkers in cancer.

Noël G, Langouo Fontsa M, Willard-Gallo K.

Semin Cancer Biol. 2018 Oct;52(Pt 2):66-74. doi: 10.1016/j.semcancer.2018.03.003. Epub 2018 Mar 21. Review.

PMID:
29574171
17.

Immune Infiltration in Invasive Lobular Breast Cancer.

Desmedt C, Salgado R, Fornili M, Pruneri G, Van den Eynden G, Zoppoli G, Rothé F, Buisseret L, Garaud S, Willard-Gallo K, Brown D, Bareche Y, Rouas G, Galant C, Bertucci F, Loi S, Viale G, Di Leo A, Green AR, Ellis IO, Rakha EA, Larsimont D, Biganzoli E, Sotiriou C.

J Natl Cancer Inst. 2018 Jul 1;110(7):768-776. doi: 10.1093/jnci/djx268.

18.

The Abscopal Effect in the Era of Cancer Immunotherapy: a Spontaneous Synergism Boosting Anti-tumor Immunity?

Hlavata Z, Solinas C, De Silva P, Porcu M, Saba L, Willard-Gallo K, Scartozzi M.

Target Oncol. 2018 Apr;13(2):113-123. doi: 10.1007/s11523-018-0556-3.

PMID:
29470785
19.

Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy.

Solinas C, Porcu M, Hlavata Z, De Silva P, Puzzoni M, Willard-Gallo K, Scartozzi M, Saba L.

Crit Rev Oncol Hematol. 2017 Dec;120:13-21. doi: 10.1016/j.critrevonc.2017.09.017. Epub 2017 Oct 10. Review.

PMID:
29198327
20.

Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.

Solinas C, Garaud S, De Silva P, Boisson A, Van den Eynden G, de Wind A, Risso P, Rodrigues Vitória J, Richard F, Migliori E, Noël G, Duvillier H, Craciun L, Veys I, Awada A, Detours V, Larsimont D, Piccart-Gebhart M, Willard-Gallo K.

Front Immunol. 2017 Oct 30;8:1412. doi: 10.3389/fimmu.2017.01412. eCollection 2017.

21.

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, Ameye L, Bareche Y, Paesmans M, Crown JPA, Di Leo A, Loi S, Piccart-Gebhart M, Willard-Gallo K, Sotiriou C, Stagg J.

Ann Oncol. 2018 Apr 1;29(4):1056-1062. doi: 10.1093/annonc/mdx730.

22.

PD-1hiCXCR5-CD4+ TFH Cells Play Defense in Cancer and Offense in Arthritis.

Gu-Trantien C, Willard-Gallo K.

Trends Immunol. 2017 Dec;38(12):875-878. doi: 10.1016/j.it.2017.10.003. Epub 2017 Oct 27.

PMID:
29111220
23.

Inflammatory Stroma of Lymphoepithelioma-like Carcinoma of the Cervix: Immunohistochemical Study of 3 Cases and Review of the Literature.

Philippe A, Rassy M, Craciun L, Naveaux C, Willard-Gallo K, Larsimont D, Veys I.

Int J Gynecol Pathol. 2018 Sep;37(5):482-487. doi: 10.1097/PGP.0000000000000446. Review.

PMID:
28985196
24.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Review.

25.

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162. Review.

26.

DNA methylation-based immune response signature improves patient diagnosis in multiple cancers.

Jeschke J, Bizet M, Desmedt C, Calonne E, Dedeurwaerder S, Garaud S, Koch A, Larsimont D, Salgado R, Van den Eynden G, Willard Gallo K, Bontempi G, Defrance M, Sotiriou C, Fuks F.

J Clin Invest. 2017 Aug 1;127(8):3090-3102. doi: 10.1172/JCI91095. Epub 2017 Jul 17.

27.

Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.

Buisseret L, Desmedt C, Garaud S, Fornili M, Wang X, Van den Eyden G, de Wind A, Duquenne S, Boisson A, Naveaux C, Rothé F, Rorive S, Decaestecker C, Larsimont D, Piccart-Gebhart M, Biganzoli E, Sotiriou C, Willard-Gallo K.

Mod Pathol. 2017 Sep;30(9):1204-1212. doi: 10.1038/modpathol.2017.43. Epub 2017 Jun 16.

28.

CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer.

Gu-Trantien C, Migliori E, Buisseret L, de Wind A, Brohée S, Garaud S, Noël G, Dang Chi VL, Lodewyckx JN, Naveaux C, Duvillier H, Goriely S, Larsimont D, Willard-Gallo K.

JCI Insight. 2017 Jun 2;2(11). pii: 91487. doi: 10.1172/jci.insight.91487. eCollection 2017 Jun 2.

29.

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.

Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M.

Cancer Treat Rev. 2017 Jun;57:8-15. doi: 10.1016/j.ctrv.2017.04.005. Epub 2017 May 2. Review.

PMID:
28525810
30.

Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.

Buisseret L, Garaud S, de Wind A, Van den Eynden G, Boisson A, Solinas C, Gu-Trantien C, Naveaux C, Lodewyckx JN, Duvillier H, Craciun L, Veys I, Larsimont D, Piccart-Gebhart M, Stagg J, Sotiriou C, Willard-Gallo K.

Oncoimmunology. 2016 Dec 14;6(1):e1257452. doi: 10.1080/2162402X.2016.1257452. eCollection 2017.

31.

FOXP1 is a regulator of quiescence in healthy human CD4+ T cells and is constitutively repressed in T cells from patients with lymphoproliferative disorders.

Garaud S, Roufosse F, De Silva P, Gu-Trantien C, Lodewyckx JN, Duvillier H, Dedeurwaerder S, Bizet M, Defrance M, Fuks F, Bex F, Willard-Gallo K.

Eur J Immunol. 2017 Jan;47(1):168-179. doi: 10.1002/eji.201646373. Epub 2016 Nov 30.

32.

Circulating (CD3(-)CD19(+)CD20(-)IgD(-)CD27(high)CD38(high)) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?

Pozdzik A, Beukinga I, Gu-Trantien C, Willard-Gallo K, Nortier J, Pradier O.

Mediators Inflamm. 2016;2016:7651024. doi: 10.1155/2016/7651024. Epub 2016 Jul 14.

33.

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.

Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, Floris G, Fox SB, Gao D, Ingold Heppner B, Kim SR, Kos Z, Kreipe HH, Lakhani SR, Penault-Llorca F, Pruneri G, Radosevic-Robin N, Rimm DL, Schnitt SJ, Sinn BV, Sinn P, Sirtaine N, O'Toole SA, Viale G, Van de Vijver K, de Wind R, von Minckwitz G, Klauschen F, Untch M, Fasching PA, Reimer T, Willard-Gallo K, Michiels S, Loi S, Salgado R.

Mod Pathol. 2016 Oct;29(10):1155-64. doi: 10.1038/modpathol.2016.109. Epub 2016 Jul 1.

34.

Characterization of human breast cancer tissues by infrared imaging.

Verdonck M, Denayer A, Delvaux B, Garaud S, De Wind R, Desmedt C, Sotiriou C, Willard-Gallo K, Goormaghtigh E.

Analyst. 2016 Jan 21;141(2):606-19. doi: 10.1039/c5an01512j.

PMID:
26535413
35.

Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome.

Fumagalli D, Gacquer D, Rothé F, Lefort A, Libert F, Brown D, Kheddoumi N, Shlien A, Konopka T, Salgado R, Larsimont D, Polyak K, Willard-Gallo K, Desmedt C, Piccart M, Abramowicz M, Campbell PJ, Sotiriou C, Detours V.

Cell Rep. 2015 Oct 13;13(2):277-89. doi: 10.1016/j.celrep.2015.09.032. Epub 2015 Oct 1.

36.

IRF5: a rheostat for tumor-infiltrating lymphocyte trafficking in breast cancer?

Garaud S, Willard-Gallo K.

Immunol Cell Biol. 2015 May-Jun;93(5):425-6. doi: 10.1038/icb.2015.39. No abstract available.

PMID:
26010613
37.

A simple and rapid protocol to non-enzymatically dissociate fresh human tissues for the analysis of infiltrating lymphocytes.

Garaud S, Gu-Trantien C, Lodewyckx JN, Boisson A, De Silva P, Buisseret L, Migliori E, Libin M, Naveaux C, Duvillier H, Willard-Gallo K.

J Vis Exp. 2014 Dec 6;(94). doi: 10.3791/52392.

38.

Label-free phenotyping of peripheral blood lymphocytes by infrared imaging.

Verdonck M, Garaud S, Duvillier H, Willard-Gallo K, Goormaghtigh E.

Analyst. 2015 Apr 7;140(7):2247-56. doi: 10.1039/c4an01855a.

PMID:
25516910
39.

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S; International TILs Working Group 2014.

Ann Oncol. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11.

40.

Tumor-infiltrating follicular helper T cells: The new kids on the block.

Gu-Trantien C, Willard-Gallo K.

Oncoimmunology. 2013 Oct 1;2(10):e26066. Epub 2013 Sep 12.

41.

CD4⁺ follicular helper T cell infiltration predicts breast cancer survival.

Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothé F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart M, Sotiriou C, Willard-Gallo K.

J Clin Invest. 2013 Jul;123(7):2873-92. doi: 10.1172/JCI67428. Epub 2013 Jun 17.

42.

State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations.

Pauwels K, Gijsbers R, Toelen J, Schambach A, Willard-Gallo K, Verheust C, Debyser Z, Herman P.

Curr Gene Ther. 2009 Dec;9(6):459-74. Review.

PMID:
20021330
43.

Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways.

Ravoet M, Sibille C, Gu C, Libin M, Haibe-Kains B, Sotiriou C, Goldman M, Roufosse F, Willard-Gallo K.

Blood. 2009 Oct 1;114(14):2969-83. doi: 10.1182/blood-2008-08-175091. Epub 2009 Jul 16.

44.

The role of NPM, p14arf and MDM2 in precursors of bronchial squamous cell carcinoma.

Mascaux C, Bex F, Martin B, Burny A, Haller A, Paesmans M, Willard-Gallo K, Ninane V, Sculier JP.

Eur Respir J. 2008 Sep;32(3):678-86. doi: 10.1183/09031936.00008408. Epub 2008 May 14.

45.

Progressive loss of CD3 expression after HTLV-I infection results from chromatin remodeling affecting all the CD3 genes and persists despite early viral genes silencing.

Akl H, Badran B, Dobirta G, Manfouo-Foutsop G, Moschitta M, Merimi M, Burny A, Martiat P, Willard-Gallo KE.

Virol J. 2007 Sep 6;4:85.

46.

HTLV-I infection of WE17/10 CD4+ cell line leads to progressive alteration of Ca2+ influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation.

Akl H, Badran BM, Zein NE, Bex F, Sotiriou C, Willard-Gallo KE, Burny A, Martiat P.

Leukemia. 2007 Apr;21(4):788-96. Epub 2007 Feb 8. Erratum in: Leukemia. 2009 Nov;23(11):2187. Zein, N E [corrected to Zein, N El].

PMID:
17287851
47.

Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.

Cardoso F, Durbecq V, Laes JF, Badran B, Lagneaux L, Bex F, Desmedt C, Willard-Gallo K, Ross JS, Burny A, Piccart M, Sotiriou C.

Mol Cancer Ther. 2006 Dec;5(12):3042-51. Epub 2006 Dec 5.

48.

Pertussis toxin activates adult and neonatal naive human CD4+ T lymphocytes.

Tonon S, Badran B, Benghiat FS, Goriely S, Flamand V, Willard-Gallo K, Willems F, Goldman M, De Wit D.

Eur J Immunol. 2006 Jul;36(7):1794-804.

49.

Defective CD3gamma gene transcription is associated with NFATc2 overexpression in the lymphocytic variant of hypereosinophilic syndrome.

Willard-Gallo KE, Badran BM, Ravoet M, Zerghe A, Burny A, Martiat P, Goldman M, Roufosse F, Sibille C.

Exp Hematol. 2005 Oct;33(10):1147-59.

PMID:
16219537
50.

6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome.

Ravoet M, Sibille C, Roufosse F, Duvillier H, Sotiriou C, Schandené L, Martiat P, Goldman M, Willard-Gallo KE.

Haematologica. 2005 Jun;90(6):753-65.

Supplemental Content

Loading ...
Support Center